Download PDF

Other users also viewed these articles

Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study Samantha Thifani Alrutz Barcelos; Amanda Souza Silva-Sperb; Helena Abadie Moraes; Larisse Longo; Bruna Concheski de Moura; Matheus Truccolo Michalczuk; Carolina Uribe-Cruz; Carlos Thadeu Schmidt Cerski; Themis Reverbel da Silveira; Valesca Dall'Alba; Mário Reis Álvares-da-Silva;
Ann Hepatol. 2023;28:
Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease Shan Hong; Yiwei Hao; Lei Sun; Ping Li; Junru Yang; Fuyang Zhang; Lingling He; Jing Zhang; Hongshan Wei;
10.1016/j.aohep.2024.101589
New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD Louise Torres; Alice Schuch; Larisse Longo; Bruna Bressan Valentini; Gabriela Schneider Galvão; Eduardo Luchese; Carlos Pinzon; Rodrigo Bartels; Mário Reis Álvares-da-Silva;
Ann Hepatol. 2023;28: